Understand the source comparison
SS-31 Contraindications: Safety Comparison
Understanding how SS-31 contraindications compare to other mitochondrial-targeted or cardioprotective peptides clarifies the specific risk profile and helps research teams select appropriate candidates for protocols. This table contrasts contraindication patte
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Understanding how SS-31 contraindications compare to other mitochondrial-targeted or cardioprotective peptides clarifies the specific risk profile and helps research teams select appropriate candidates for protocols. This table contrasts contraindication patterns across four mechanistically distinct peptide classes.
- SS-31 (Elamipretide)
- Cardiolipin stabilization, cristae remodeling
- Pregnancy/lactation, eGFR <30 mL/min, active malignancy, known peptide hypersensitivity
- Moderate CKD (eGFR 30–59), concurrent nephrotoxins, Complex IV deficiencies, decompensated cirrhosis
- High. Dose adjustment required for eGFR <60
- Requires comprehensive renal and oncology screening; unsuitable for patients with proliferative disease or severe kidney impairment
- MK 677 (Ibutamoren)
- Growth hormone secretagogue, ghrelin mimetic
- Active malignancy, uncontrolled diabetes (HbA1c >9%), severe heart failure (NYHA Class IV)
- Moderate heart failure, prediabetes, obstructive sleep apnea
- Low. Hepatic metabolism predominates
- Growth hormone elevation contraindicates use in active cancer; insulin resistance requires glucose monitoring
- Cerebrolysin
- Neurotrophic peptide mixture, BDNF modulation
- Epilepsy or seizure disorders, acute cerebrovascular events
- Renal impairment (eGFR <45), hepatic dysfunction, concurrent MAOIs
- Moderate. Both renal and hepatic pathways
- Neurotrophic effects contraindicate use in seizure-prone patients; requires EEG baseline in neurological conditions
- ARA 290
- Tissue-protective erythropoietin receptor agonist
- Active thromboembolic disease, polycythemia vera, uncontrolled hypertension (>160/100 mmHg)
- Cardiovascular disease, hypercoagulable states
- Low to moderate. Renal clearance without accumulation in mild-moderate CKD
- Erythropoietic pathway involvement contraindicates use in thrombotic or proliferative hematologic conditions
- SS-31's renal clearance dependency is more pronounced than other peptides in this class. Unlike MK 677, which undergoes hepatic metabolism, or ARA 290, which distributes across tissue-protective pathways without significant renal accumulation, SS-31 exhibits a steep pharmacokinetic curve in patients with declining eGFR. Research protocols using SS-31 require baseline and interval serum creatinine measurement. A step not universally necessary for growth hormone secretagogues or neurotrophic peptides.
- The active malignancy contraindication applies across multiple peptide classes but for different reasons. For SS-31, the concern is mitochondrial enhancement in metabolically active tumors. For MK 677, it's growth hormone's proliferative signaling through IGF-1 pathways. For ARA 290, it's erythropoietin receptor activation in certain hematologic malignancies. Each mechanism demands cancer history screening, but SS-31's contraindication extends specifically to tumors with high oxidative phosphorylation activity. Renal cell carcinoma, hepatocellular carcinoma, and certain melanoma subtypes.